Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases.It binds to the alpha subunit of the interleukin-4 receptor. Through blockade of IL-4R alpha, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease.
This drug was developed by Regeneron Pharmaceuticals.
On May 21/2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating a 87% reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma.
The long-standing alliance between Sanofi and Regeneron looks to have scored another clinical goal, this time with dupilumab for asthma.
The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation. The 104-patient study enrolled 104 patients with moderate-to-severe, persistent…
View original post 24 more words